MXCT Insider Trading

Insider Ownership Percentage: 3.00%
Insider Buying (Last 12 Months): $489,113.29
Insider Selling (Last 12 Months): $622,335.08

MaxCyte Insider Trading History Chart

This chart shows the insider buying and selling history at MaxCyte by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$10M-$5M$0$5M$10MTotal Insider BuyingTotal Insider Selling

MaxCyte Share Price & Price History

Current Price: $2.58
Price Change: Price Increase of +0.24 (10.26%)
As of 04/11/2025 05:00 PM ET

This chart shows the closing price history over time for MXCT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$2.58Closing price on 04/11/25:

SEC Filings (Institutional Ownership Changes) for MaxCyte (NASDAQ:MXCT)

68.81% of MaxCyte stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at MXCT by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$38kbought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$20M-$10M$0$10M$20MTotal InflowsTotal Outflows
MaxCyte logo
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Read More on MaxCyte

Today's Range

Now: $2.58
Low: $2.30
High: $2.58

50 Day Range

MA: $3.34
Low: $2.33
High: $4.62

52 Week Range

Now: $2.58
Low: $2.21
High: $5.26

Volume

445,053 shs

Average Volume

526,412 shs

Market Capitalization

$274.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.39

Who are the company insiders with the largest holdings of MaxCyte?

MaxCyte's top insider investors include:
  1. Douglas Doerfler (CEO)
  2. Stanley C Erck (Director)
  3. John Joseph Johnston (Director)
  4. Douglas J Swirsky (CFO)
  5. Maher Masoud (CEO)
  6. David I Sandoval (General Counsel)
  7. Ali Soleymannezhad (Insider)
  8. Thomas M Ross (EVP)
  9. Thomas M Ross (EVP)
Learn More about top insider investors at MaxCyte.

Who are the major institutional investors of MaxCyte?

MaxCyte's top institutional shareholders include:
  1. Kwmg LLC — 0.01%
Learn More about top institutional investors of MaxCyte stock.

Which major investors are buying MaxCyte stock?

Within the previous quarter, MXCT stock was acquired by institutional investors including:
  1. Kwmg LLC